19 October 2009
The effects of alprazolam on tinnitus: a cross-over randomized clinical trial
Mir Mohammad JalaliABCDEFG, Abdorrahim KoushaAB, Sayed Ebrahim NaghaviAB, Robabeh SoleimaniABDF, Rozbeh BananBFMed Sci Monit 2009; 15(11): PI55-60 :: ID: 878223
Abstract
Background
Tinnitus remains a phenomenon with an unknown pathophysiology and for which few therapeutic measures are available. To date there has been insufficient evidence to support the use of alprazolam in the treatment of tinnitus. We sought to evaluate the efficacy of alprazolam for relief of tinnitus.
Material and Method
Thirty-six tinnitus sufferers participated in this cross-over, randomized, triple-blind, placebo-controlled trial. Inclusion criteria included patients between ages 21 and 65, with a complaint of non-pulsatile tinnitus of more than 1 year duration. Patients with depressive or anxiety disorders were excluded, as were those using hearing aids. Participants received alprazolam 1.5 mg daily versus placebo in each period. Primary outcome variables included the Tinnitus Handicap Inventory (THI), a Visual Analog Scale (VAS), and tinnitus loudness.
Results
Thirty patients completed the study. The average age of patients was 47.58+/-7.65 years. Alprazolam in comparison with placebo did not result in statistically significantly greater relief in THI score and tinnitus loudness. There was a significant improvement in VAS score in the alprazolam group compared with the placebo group (p<0.001).
Conclusions
These results suggest that although alprazolam did not improve the THI score or sensation level of loudness significantly, it has a desirable effect on VAS. Further work is needed to determine the beneficial effects of alprazolam in distressed or depressed patients.
Keywords: Tinnitus - drug therapy, Placebos, Pain Measurement, Cross-Over Studies, Auditory Threshold - drug effects, Anti-Anxiety Agents - therapeutic use, Alprazolam - therapeutic use, young adult
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Evaluating Pelvic Floor Dysfunction in Female Horse Show Jumpers Using the Australian Pelvic Floor Question...Med Sci Monit In Press; DOI: 10.12659/MSM.946830
Clinical Research
Predictive Value of Platelet Aggregation Tests in Recurrent Cerebral Ischemia and Major BleedingMed Sci Monit In Press; DOI: 10.12659/MSM.947172
Clinical Research
Impact of Nurse-Led Versus Surgeon-Led Preoperative Counseling and Follow-Up on Postoperative Outcomes in P...Med Sci Monit In Press; DOI: 10.12659/MSM.945597
Clinical Research
Evaluation of Attitudes to Learning Doctor-Patient Communication Skills in 427 Postgraduate Doctors Using t...Med Sci Monit In Press; DOI: 10.12659/MSM.947276
Most Viewed Current Articles
17 Jan 2024 : Review article 6,973,921
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,258
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,430
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 21,545
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912